Cargando…

Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies

BACKGROUND: Little is known about pathogen-specific humoral immunity after chimeric antigen receptor–modified T (CAR-T) cell therapy for B cell malignancies. METHODS: We conducted a prospective cross-sectional study of CD19-targeted or B cell maturation antigen–targeted (BCMA-targeted) CAR-T cell th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Walti, Carla S., Krantz, Elizabeth M., Maalouf, Joyce, Boonyaratanakornkit, Jim, Keane-Candib, Jacob, Joncas-Schronce, Laurel, Stevens-Ayers, Terry, Dasgupta, Sayan, Taylor, Justin J., Hirayama, Alexandre V., Bar, Merav, Gardner, Rebecca A., Cowan, Andrew J., Green, Damian J., Boeckh, Michael J., Maloney, David G., Turtle, Cameron J., Hill, Joshua A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2021
Materias:	Clinical Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262349/ https://www.ncbi.nlm.nih.gov/pubmed/33914708 http://dx.doi.org/10.1172/jci.insight.146743

Ejemplares similares

196. Antibodies to Vaccine-preventable Infections After CAR-T Cell Immunotherapy for B Cell Malignancies
por: Walti, Carla S, et al.
Publicado: (2020)

Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy
por: Walti, Carla S., et al.
Publicado: (2021)

Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study
por: Walti, Carla S, et al.
Publicado: (2021)

491. Characterizing the Association of Pre-Existing Cytomegalovirus (CMV)-specific Humoral Immunity with CMV Reactivation Risk after Hematopoietic Cell Transplantation (HCT)
por: Zamora, Danniel, et al.
Publicado: (2022)

Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy
por: Juluri, Krishna R., et al.
Publicado: (2022)

20. Risk Factors for Breakthrough Cytomegalovirus (CMV) Infection and De Novo Resistance in Hematopoietic Cell Transplantation (HCT) Recipients Receiving Letermovir Prophylaxis
por: Zamora, Danniel, et al.
Publicado: (2021)

Comparison of Humoral and T-Cell Response after Sars-Cov-2 Vaccination Among Patients before and after Chimeric Antigen Receptor-Modified T Cell (CAR-T cell) Therapy
por: Gonzalez, Michael A, et al.
Publicado: (2022)

Cytokines in CAR T Cell–Associated Neurotoxicity
por: Gust, Juliane, et al.
Publicado: (2020)

Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL
por: Liang, Emily C., et al.
Publicado: (2023)

2711. Viral encephalitis after chimeric antigen receptor (CAR)-modified T-cell therapy: A Retrospective Cohort Study
por: Kampouri, Eleftheria, et al.
Publicado: (2023)

Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy
por: Sheih, Alyssa, et al.
Publicado: (2020)

2712. Respiratory syncytial virus (RSV) pre-fusion F antibody titers in hematopoietic cell transplant recipients with upper versus lower respiratory tract infections
por: Kim, Sara R, et al.
Publicado: (2023)

P616: LONG-TERM FOLLOW-UP UPDATE AND MULTIVARIABLE ANALYSES OF FACTORS ASSOCIATED WITH DURATION OF RESPONSE AFTER CD19 CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY CLL
por: Liang, Emily, et al.
Publicado: (2023)

A human coronavirus evolves antigenically to escape antibody immunity
por: Eguia, Rachel T., et al.
Publicado: (2021)

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL
por: Gauthier, Jordan, et al.
Publicado: (2022)

Humoral and cellular responses to SARS-CoV-2 vaccines before and after chimeric antigen receptor–modified T-cell therapy
por: Gonzalez, Michael A., et al.
Publicado: (2022)

Innovation in BCMA CAR-T therapy: Building beyond the Model T
por: Banerjee, Rahul, et al.
Publicado: (2022)

Predictors of response to axicabtagene‐ciloleucel CAR T cells in aggressive B cell lymphomas: A real‐world study
por: Iovino, Lorenzo, et al.
Publicado: (2022)

A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy
por: Hirayama, Alexandre V., et al.
Publicado: (2022)

Novel Observation: Northern Cardinal (Cardinalis cardinalis) Perches on an Invasive Jorō Spider (Trichonephila clavata) Web and Steals Food
por: Schronce, Arty, et al.
Publicado: (2022)

2307. Risk factors for Cytomegalovirus (CMV) reactivation and Association with Clinical Outcomes in Critically Ill Adults with Sepsis: A Pooled Analysis of Prospective Studies
por: Imlay, Hannah, et al.
Publicado: (2019)

Convergent clonal selection of donor- and recipient-derived CMV-specific T cells in hematopoietic stem cell transplant patients
por: Erickson, Jami R., et al.
Publicado: (2022)

Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?
por: Frigault, Matthew J., et al.
Publicado: (2020)

2591. The Role of Neutralizing Antibodies (nAb) Against Cytomegalovirus (CMV) Epithelial Cell-entry in Patients with Self-limited (SL) CMV infection after Hematopoietic Cell Transplantation (HCT)
por: Zamora, Danniel, et al.
Publicado: (2019)

2109. HHV-6 and EBV Reactivation after Allogeneic Hematopoietic Cell Transplantation in the Era of Letermovir for CMV Prophylaxis: A Retrospective Cohort Study
por: Kampouri, Eleftheria, et al.
Publicado: (2022)

P1097: CD20 CAR-T THERAPY WITH MB-106 FOR BTK INHIBITOR-REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA (WM)/ LYMPHOPLASMACYTIC LYMPHOMA (LPL) – SINGLE INSTITUTION STUDY
por: Shadman, Mazyar, et al.
Publicado: (2023)

Techniques to Study Antigen-Specific B Cell Responses
por: Boonyaratanakornkit, Jim, et al.
Publicado: (2019)

2291. SARS-CoV-2 Viral Kinetics Among Immunologically Naïve Adults: Comparison by Variant and Reinfection Status
por: Doll, Margaret K, et al.
Publicado: (2023)

Parallel evolution of influenza across multiple spatiotemporal scales
por: Xue, Katherine S, et al.
Publicado: (2017)

2094. A prospective multicenter study of HHV-6B genomic DNA and gene transcription in paired bronchoalveolar lavage fluid and blood from HCT recipients
por: Hill, Joshua A, et al.
Publicado: (2022)

Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL
por: Zurko, Joanna, et al.
Publicado: (2022)

DNA nanostructures: A versatile lab-bench for interrogating biological reactions
por: Lee, Andrew J., et al.
Publicado: (2019)

Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy
por: Kilgour, Marisa K., et al.
Publicado: (2023)

Toxicity and management in CAR T-cell therapy
por: Bonifant, Challice L, et al.
Publicado: (2016)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Tuning the performance of CAR T cell immunotherapies
por: Richardson, Noah H., et al.
Publicado: (2019)

Chimeric antigen receptor-modified T cells derived from defined CD8(+) and CD4(+) subsets confer superior antitumor reactivity in vivo
por: Sommermeyer, Daniel, et al.
Publicado: (2015)

Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design
por: Drent, Esther, et al.
Publicado: (2018)

Turn to TCRs when CARs fail
por: Stauss, Hans J.
Publicado: (2017)

Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma
por: Panjwani, M. Kazim, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5lbk7hngcmh8kunt83ag4uvco6